Hypoxia-inducible factor-1alpha suppressing apoptosis and increasing tolerance of lung cancer cells to chemotherapy

Abstract

In order to construct plasmid of hypoxia-inducible factor-lalpha (HIF-1α), and transfect into human lung cancer cells A549, the change in sensitivity of lung cancer cells A549 to chemotherapy was observed. HIF-1α mRNA structure region was amplified by RT-PCR and inserted into plasmid pcDNA3. The expression plasmid pcDNA3/HIF-1α was transfected into A549 with Lipofec-tAMINE™2000. The expression of HIF-1α protein was detected by Western blot. After A549 cells were transfected with HIF-1α prior to addition of 5-Fu, the growth activity was measured by growth curve, apoptosis was detected by flow cytometry at 48 h, and the levels of caspase3 and MDR-1 were determined by Western blot. The results showed that the constructed expression plasmid was analyzed with restriction enzymes and gel electrophoresis. Two DNA lanes at 2.55 kb and 5.4 kb respectively were found, which were consistent with that expected. The growth rate in 5-Fu group was significantly inhibited, and the apoptosis index and caspase3 activity were increased significantly as compared with control group. After HIF-1α being transfected into A549, the activity of MDR-1 was increased and the effect of 5-Fu was weakened. In conclusion, HIF-1α can promote chemoresistance by increasing the activation of MDR1 and suppressing apoptosis during lung cancer cells A549 induced with 5-Fu.

Keywords

HIF-1α / chemotherapy / lung cancer

References

[1] DangC. V., SemenzaG. L.. Oncogenic alterations of metabolism. Trends Biochem Sci, 1999, 24(2): 68-72

[2] AxelsonH., FredlundE., OvenbergerM., et al.. Hypoxia-induced dedifferentiation of tumor cells — a mechanism behind heterogeneity and aggressiveness of solid tumors. Semin Cell Dev Biol, 2005, 16(4–5): 554-563

[3] ClottesE.. Hypoxia-inducible factor 1: regulation, involvement in carcinogenesis and target for anticancer therapy. Bull Cancer, 2005, 92(2): 119-127

[4] IyerN. V., KotchL. E., AganiF., et al.. Cellular and developmental control of O₂ homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev, 1998, 12(2): 149-162

[5] WangG. L., JiangB. H., RueE. A., et al.. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O₂ tension. Proc Natl Acad Sci U S A, 1995, 92(12): 5510-5514

[6] SemenzaG. L.. HIF-1 and human disease: one highly involved factor. Genes Dev, 2000, 14(16): 1983-1991

[7] TeicherB. A.. Physiologic mechanisms of therapeutic resistance. Hematol Oncol Clin North Am, 1995, 9(2): 475-506

[8] LiuJ. R., ChenB. Q., YangY. M., et al.. Effect of apoptosis on gastric adenocarcinoma cell line SGC-7901 induced by cis-9, trans-11-conjugated linoleic acid. World J Gastroenterol, 2002, 8(6): 999-1004

[9] EpsteinA. C., GleadleJ. M., McNeillL. A., et al.. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell, 2001, 107(1): 43-54

[10] BruickR. K., McKnightS. L.. A conserved family of prolyl-4-hydroxylases that modify HIF. Science, 2001, 294(5545): 1337-1340

[11] GottesmanM. M., PastanI.. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem, 1993, 62: 385-427

[12] BurgerH., FoekensJ. A., LookM. P., et al.. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res, 2003, 9(2): 827-836

[13] van de DonkN. W., KamphuisM. M., van DijkM., et al.. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein. Leukemia, 2003, 17(1): 211-219